The 44.8% ORR in late-line CRC is promising for a novel ADC target, but the data are early and from a small cohort. Monitor Phase 1b dose optimization results in 2027 and any further OrbiMed filings for stake changes.
Price Chart
Executive Summary
ArriVent BioPharma announced encouraging initial Phase 1 results for ARR-217, a CDH17-targeting ADC, in heavily pretreated gastrointestinal cancer patients, with a 44.8% ORR at the 6 mg/kg dose in colorectal cancer. The data support advancement into Phase 1b dose optimization, with further data expected in 2027. The filing is positive for the pipeline but early-stage, and the recent OrbiMed stake reduction tempers the bullish read.
Key Facts
- 44.8% ORR (13/29) at 6 mg/kg Q3W in pretreated CRC patients
- 93.1% DCR (27/29) at 6 mg/kg Q3W
- Grade 3+ TRAE 20.4% at 6 mg/kg; no Grade 5 TRAE or ILD
- Phase 1b dose optimization at 5 and 6 mg/kg Q3W underway; data expected 2027
- OrbiMed reduced stake by 151,366 shares on Oct 6, 2026, now holds 5.8%
Financial Impact
Early-stage clinical data; no financial terms disclosed. Market cap ~$947M.
Risk Factors
- Early-stage data; Phase 1b results may differ
- OrbiMed's recent sale of 151,366 shares suggests some insider/activist profit-taking
- Competitive ADC landscape in GI cancers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3387735 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $23.64 | awaiting T+5 | — | $15.36 (−35.03%) |
Oct 25, 2026 1d ago | Press Release | $21.00 | awaiting T+5 | — | $15.36 (−26.86%) |
Oct 23, 2026 3d ago | Press Release | $21.00 | awaiting T+5 | — | $15.36 (−26.86%) |
Oct 19, 2026 7d ago | 8-K | $17.94 $15.36 | ▼ −14.38% | ▼ −14.24% | $15.36 (−14.38%) |
Oct 13, 2026 13d ago | SC 13G | $16.20 $19.12 | ▲ +18.02% | ▲ +17.57% | $15.36 (−5.19%) |
Oct 13, 2026 13d ago | 8-K | $16.09 $18.85 | ▲ +17.15% | ▲ +18.31% | $15.36 (−4.54%) |
Oct 8, 2026 18d ago | SC 13D/A | $16.73 $16.66 | ▲ +0.42% | ▼ −1.55% | $15.36 (+8.19%) |
Oct 6, 2026 20d ago | 8-K | $15.09 $16.09 | ▼ −6.63% | ▼ −6.77% | $15.36 (−1.79%) |
Aug 12, 2026 10w ago | Press Release | $30.00 $29.18 | ▲ +2.73% | ▲ +0.77% | $15.36 (+48.80%) |
Jun 11, 2026 19w ago | Institutional Cluster | $30.54 $31.74 | ▲ +3.93% | ▲ +3.26% | $15.36 (−49.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers